Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01778491 · ClinicalTrials.gov registry record
AMD Phenotype and Genotype Study
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 344
- Enrollment target
NCT01778491: Completed study, sponsored by National Eye Institute (NEI).
NCT01778491 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 344 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01778491 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 344 participants
- Enrollment target
Study Summary
Background: \- Age-related macular degeneration (AMD) is a disease that blurs the sharp vision needed for activities such as reading, sewing, and driving. It affects the macula, the center of the retina at the back of the eye, which allows a person to see fine detail. Researchers want to collect medical histories, eye exam data, and genetic information that may be associated with AMD. They want to compare this information with information collected from people without AMD. Objectives: \- To collect medical information and gene samples for researchers studying AMD. Eligibility: * Individuals between and 60 and 90 years of age who have AMD in at least one eye. * Individuals between and 60 and 90 years of age who have no AMD in either eye. Design: * This study will involve one study visit. This study visit will last 6 to 8 hours. * Participants will have the following tests and exams as part of their study visit: * Full physical exam and medical history * Full eye examination * Laser scan of the eye * Retina function test * Vision sensitivity test * Optional blood sample (for genetic study) * No treatment will be provided as part of this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2012-11-05 |
| Est. Completion | 2015-09-29 |
What the finished NCT01778491 record still lists
NCT01778491 is an observational study that tracks outcomes without assigning an intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01778491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01778491 about?
NCT01778491 is a clinical study titled "AMD Phenotype and Genotype Study". Background: \- Age-related macular degeneration (AMD) is a disease that blurs the sharp vision needed for activities such as reading, sewing, and driving. It affects the macula, the center of the retina at the back of the eye, which allows a person to see fine detail. Researchers want to collect me...
What is the current status of trial NCT01778491?
This trial is currently completed. The enrollment target is 344 participants. The study started on 2012-11-05. Estimated completion is 2015-09-29.
Who is sponsoring clinical trial NCT01778491?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI